CTTNBP2

Across TCGA pan-cancer cohorts, CTTNBP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTTNBP2 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CTTNBP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTTNBP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where CTTNBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.862	0.484	<.001	31	view →
CCRCC	DFS	Median	All	0.867	0.621	.008	13	view →
GBM	DFS	Tertile	All	0.789	0.686	.034	4	view →
LSCC	OS	Tertile	II,III,IV	0.908	0.439	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTTNBP2–HNSC (DFS)

Open the HNSC breakdown →